Education Sessions

Cancer Genomics and Tumor Immunotherapy Symposium 2018
Friday, November 16, 2018; Toronto MaRS Discovery District, Toronto, Ontario

The Princess Margaret Cancer Genomics Program (CGP) and Tumor Immunotherapy Program (TIP) are jointly hosting the “Cancer Genomics and Tumor Immunotherapy Symposium: A Clinical Perspective” to take place at the MaRS Discovery District (Toronto, Canada) on Friday November 16, 2018. The Symposium will include focused talks and panel discussions on cancer genomics in the morning and tumor immunotherapy in the afternoon. International, national, and local speakers will share emerging therapies and technologies aimed at increasing the personalized approach to treatment, and genomics applications in the clinic, and new research in the field of microbial genomics.

The target audience for this meeting includes academic and community oncologists, pharmaceutical leaders, regulatory agencies, basic and translational scientists and trainees. We envision this symposium to provide a clinical and translational perspective on genomics and immunotherapy as it applies to precision cancer medicine at the point of care.

For more information, please visit

Canadian Cancer Immunotherapy Consortium (CCIC) 2019 – Annual Symposium
Fall 2019 – Toronto (exact date and location tbd)

Incorporation of immunotherapy into standards of care will require a new generation of basic and clinical scientists who are well-versed in tumor immunology, as well as an infrastructure capable of monitoring immune activity and treatment outcomes. To this end, the Canadian Cancer Immunotherapy Consortium (CCIC) formed in 2008 as a forum to bring together Canadian scientists and clinicians with interest in advancing clinical translation of cancer immunotherapy. The founding members of the CCIC are (from east to west) Réjean Lapointe, (Université de Montréal), Jonathan Bramson, (McMaster University), Pamela Ohashi, (Princess Margaret Cancer Centre) and Brad Nelson (BC Cancer Agency).

The CCIC is an organization for the development, advancement and promotion of cancer immunotherapy in Canada, through 3 founding principles:
  1. Interaction – exchange of information and education among basic researchers and clinicians
  2. Innovation – develop and apply novel immune therapies
  3. Leadership – provide guidance to integrate the Canadian landscape with global initiatives

The CCIC is committed to the advancement and training of young scientists and it is our vision that the organization will be pivotal in knowledge dissemination in order to raise the profile of Canadians in immunotherapy. More information, including the CCIC strategic plan, is available at